ITRM20010356A1 - "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. - Google Patents

"5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.

Info

Publication number
ITRM20010356A1
ITRM20010356A1 IT2001RM000356A ITRM20010356A ITRM20010356A1 IT RM20010356 A1 ITRM20010356 A1 IT RM20010356A1 IT 2001RM000356 A IT2001RM000356 A IT 2001RM000356A IT RM20010356 A ITRM20010356 A IT RM20010356A IT RM20010356 A1 ITRM20010356 A1 IT RM20010356A1
Authority
IT
Italy
Prior art keywords
sub
ligands
halogen
triptamin
serotonin receptor
Prior art date
Application number
IT2001RM000356A
Other languages
English (en)
Italian (it)
Inventor
Cesare Maria Assunta Di
Patrizia Minetti
Giorgio Tarzia
Gilberto Spadoni
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to IT2001RM000356A priority Critical patent/ITRM20010356A1/it
Publication of ITRM20010356A0 publication Critical patent/ITRM20010356A0/it
Priority to PCT/IT2002/000398 priority patent/WO2003000252A1/en
Priority to HK05101226.9A priority patent/HK1068792B/xx
Priority to US10/481,433 priority patent/US7098233B2/en
Priority to PT02745793T priority patent/PT1404317E/pt
Priority to CA2455296A priority patent/CA2455296C/en
Priority to PL02367618A priority patent/PL367618A1/xx
Priority to JP2003506898A priority patent/JP4683839B2/ja
Priority to MXPA03011510A priority patent/MXPA03011510A/es
Priority to CNB02814337XA priority patent/CN100482223C/zh
Priority to ES02745793T priority patent/ES2319107T3/es
Priority to HU0400250A priority patent/HUP0400250A3/hu
Priority to DK02745793T priority patent/DK1404317T3/da
Priority to BR0210538-1A priority patent/BR0210538A/pt
Priority to EP02745793A priority patent/EP1404317B1/en
Priority to DE60230270T priority patent/DE60230270D1/de
Priority to AU2002317482A priority patent/AU2002317482B2/en
Priority to SK38-2004A priority patent/SK287828B6/sk
Priority to CZ20033314A priority patent/CZ20033314A3/cs
Priority to AT02745793T priority patent/ATE416767T1/de
Priority to KR1020037016564A priority patent/KR100885308B1/ko
Publication of ITRM20010356A1 publication Critical patent/ITRM20010356A1/it
Priority to CY20091100260T priority patent/CY1108879T1/el
Priority to JP2010204733A priority patent/JP2011016835A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
IT2001RM000356A 2001-06-21 2001-06-21 "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. ITRM20010356A1 (it)

Priority Applications (23)

Application Number Priority Date Filing Date Title
IT2001RM000356A ITRM20010356A1 (it) 2001-06-21 2001-06-21 "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
KR1020037016564A KR100885308B1 (ko) 2001-06-21 2002-06-17 ５－ｈｔ6 및／또는 ５－ｈｔ7 세로토닌 수용체의리간드로서 사용되는 ５－할로-트립타민 유도체
ES02745793T ES2319107T3 (es) 2001-06-21 2002-06-17 Derivados de 5-halo-triptamina usados como ligandos de los receptores de serotonina 5-ht6 y/o 5-ht7.
DK02745793T DK1404317T3 (da) 2001-06-21 2002-06-17 5-Halogentryptaminderivater til anvendelse som ligander af 5-HT6- og/eller 5-HT7-serotoninreceptorer
US10/481,433 US7098233B2 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands on the 5-HT6 and/or 5-HT7 serotonin receptors
PT02745793T PT1404317E (pt) 2001-06-21 2002-06-17 Derivados de 5-halo-triptamina utilizados como ligandos dos receptores serotoninérgicos 5-ht6 e/ou 5-ht7
CA2455296A CA2455296C (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors
PL02367618A PL367618A1 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht 7 serotonin receptors
JP2003506898A JP4683839B2 (ja) 2001-06-21 2002-06-17 ５−ｈｔ６および／または５−ｈｔ７セロトニン受容体のリガンドとして使用される５−ハロ−トリプタミン誘導体
MXPA03011510A MXPA03011510A (es) 2001-06-21 2002-06-17 Derivados de5-halo-triptamina usados como ligandos de receptores de serotonina 5-ht-6 y/o 5-ht-7.
CNB02814337XA CN100482223C (zh) 2001-06-21 2002-06-17 用作5-ht6和/或5-ht75-羟色胺受体的配体的5-卤代-色胺衍生物
PCT/IT2002/000398 WO2003000252A1 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors
HU0400250A HUP0400250A3 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors, their preparation and their use for preparation of pharmaceutical compositions
HK05101226.9A HK1068792B (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors
BR0210538-1A BR0210538A (pt) 2001-06-21 2002-06-17 Derivados de 5-halotriptamina usados como ligantes dos receptores de serotonina 5-ht6 e/ou 5-ht7
EP02745793A EP1404317B1 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-ht 6? and/or 5-ht 7? serotonin receptors
DE60230270T DE60230270D1 (de) 2001-06-21 2002-06-17 5-halo-tryptaminderivate als 5-ht6 und/oder 5-ht7 rezeptorliganden
AU2002317482A AU2002317482B2 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-HT6 and/or 5-HT7 serotonin receptors
SK38-2004A SK287828B6 (sk) 2001-06-21 2002-06-17 5-Halo-tryptamine derivatives used as ligands of 5-HT6 and/or 5-HT7 serotonin receptors
CZ20033314A CZ20033314A3 (cs) 2001-06-21 2002-06-17 Použití Q@halogentryptaminových derivátů jako ligandů Q@HT@ a@nebo Q@HT@ receptorů pro serotonin
AT02745793T ATE416767T1 (de) 2001-06-21 2002-06-17 5-halo-tryptaminderivate als 5-ht6 und/oder 5-ht7 rezeptorliganden
CY20091100260T CY1108879T1 (el) 2001-06-21 2009-03-06 Παραγωγα 5-αλο-τρυπταμινης που χρησιμοποιουνται ως συνδετες των σεροτονικων υποδοχεων 5-ητ6 και/ή 5-ητ7
JP2010204733A JP2011016835A (ja) 2001-06-21 2010-09-13 ５−ｈｔ６および／または５−ｈｔ７セロトニン受容体のリガンドとして使用される５−ハロ−トリプタミン誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001RM000356A ITRM20010356A1 (it) 2001-06-21 2001-06-21 "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.

Publications (2)

Publication Number Publication Date
ITRM20010356A0 ITRM20010356A0 (it) 2001-06-21
ITRM20010356A1 true ITRM20010356A1 (it) 2002-12-23

Family

ID=11455609

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2001RM000356A ITRM20010356A1 (it) 2001-06-21 2001-06-21 "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.

Country Status (21)

Country Link
US (1) US7098233B2 (enExample)
EP (1) EP1404317B1 (enExample)
JP (2) JP4683839B2 (enExample)
KR (1) KR100885308B1 (enExample)
CN (1) CN100482223C (enExample)
AT (1) ATE416767T1 (enExample)
AU (1) AU2002317482B2 (enExample)
BR (1) BR0210538A (enExample)
CA (1) CA2455296C (enExample)
CY (1) CY1108879T1 (enExample)
CZ (1) CZ20033314A3 (enExample)
DE (1) DE60230270D1 (enExample)
DK (1) DK1404317T3 (enExample)
ES (1) ES2319107T3 (enExample)
HU (1) HUP0400250A3 (enExample)
IT (1) ITRM20010356A1 (enExample)
MX (1) MXPA03011510A (enExample)
PL (1) PL367618A1 (enExample)
PT (1) PT1404317E (enExample)
SK (1) SK287828B6 (enExample)
WO (1) WO2003000252A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039127A1 (es) * 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US8086315B2 (en) 2004-02-12 2011-12-27 Asap Medical, Inc. Cardiac stimulation apparatus and method for the control of hypertension
CA2557158A1 (en) * 2004-02-20 2005-09-01 Astellas Pharma Inc. Prophylactic antimigraine agents
US20080171788A1 (en) * 2005-02-08 2008-07-17 Shinobu Akuzawa Medicament For Irritable Bowel Syndrome
EP1923387B1 (en) 2005-08-08 2011-10-19 Astellas Pharma Inc. Acylguanidine derivative or salt thereof
WO2007046112A1 (en) * 2005-10-19 2007-04-26 Suven Life Sciences Inc. Arylthioether tryptamine derivatives as functional 5-ht6 ligands
WO2007097276A1 (ja) * 2006-02-20 2007-08-30 Astellas Pharma Inc. ピロール誘導体またはその塩
EP2120950B1 (en) * 2007-03-21 2012-07-04 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain
EP2209380A4 (en) * 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CA2842455A1 (en) * 2011-08-05 2013-02-14 Sucampo Ag Method for treating schizophrenia
CN102816103B (zh) * 2012-08-20 2014-05-07 冉瑞琼 硫化天冬氨酸修饰的退黑素衍生物及其应用
US9008769B2 (en) 2012-12-21 2015-04-14 Backbeat Medical, Inc. Methods and systems for lowering blood pressure through reduction of ventricle filling
US9370662B2 (en) 2013-12-19 2016-06-21 Backbeat Medical, Inc. Methods and systems for controlling blood pressure by controlling atrial pressure
CN104529865B (zh) * 2014-12-12 2017-02-01 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
US10342982B2 (en) 2015-09-11 2019-07-09 Backbeat Medical, Inc. Methods and systems for treating cardiac malfunction
US10485658B2 (en) 2016-04-22 2019-11-26 Backbeat Medical, Inc. Methods and systems for controlling blood pressure
CN108926565A (zh) * 2017-05-26 2018-12-04 中国科学院上海生命科学研究院 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用
EP3813810A4 (en) * 2018-06-21 2022-03-30 Robert John Petcavich METHODS OF INDUCING DENDRITICAL AND SYNAPTIC GENESIS IN CHRONIC NEURODEGENERATIVE DISEASES
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
LT4084791T (lt) * 2020-02-18 2025-02-25 Gilgamesh Pharmaceuticals, Inc. Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
WO2021116503A2 (en) * 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
WO2022061196A1 (en) * 2020-09-18 2022-03-24 Mydecine Innovations Group Inc. Novel formulations of psilocybin and psilocin compounds as serotonin agonists in combination with 3,4 methylenedioxymethamphetamine (mdma)
KR20240013170A (ko) 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
US20240343692A1 (en) * 2021-08-09 2024-10-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective psychedelic compounds
CA3238440A1 (en) * 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
CN114573578B (zh) * 2022-02-16 2023-11-17 烟台宁远药业有限公司 一种烷基取代氮杂吲哚的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825734A (en) * 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
FR2315277A1 (fr) * 1975-06-25 1977-01-21 Anvar Nouveaux derives pentacycliques, leur preparation et les compositions qui les contiennent
US4428877A (en) * 1978-07-12 1984-01-31 Richter Gedeon Vegyeszeti Gyar Rt. Cis-10-bromo-E-homoeburnanes
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
FR2712591B1 (fr) * 1993-11-19 1996-02-09 Pf Medicament Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
US5688807A (en) * 1994-03-11 1997-11-18 Eli Lilly And Company Method for treating 5HT2B receptor related conditions
US5504101A (en) * 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
WO1998000400A1 (en) * 1996-06-28 1998-01-08 Meiji Seika Kaisha, Ltd. Tetrahydrobenzindole compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
AU767009B2 (en) * 1998-12-11 2003-10-30 Virginia Commonwealth University Selective 5-HT6 receptor ligands
US6403808B1 (en) * 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
EP1173432B9 (en) * 1999-04-21 2008-10-15 NPS Allelix Corp. Piperidine-indole compounds having 5-ht6 affinity
AU779832B2 (en) 1999-08-12 2005-02-10 Nps Pharmaceuticals, Inc. Azaindoles having serotonin receptor affinity
WO2004041781A1 (en) * 2002-11-07 2004-05-21 Suven Life Sciences Limited Preparation of 3-aminoalkyl-substituted indole derivatives from phenylhydrazines and aminoketones

Also Published As

Publication number Publication date
DE60230270D1 (de) 2009-01-22
PT1404317E (pt) 2009-02-23
BR0210538A (pt) 2004-06-22
CY1108879T1 (el) 2014-07-02
KR100885308B1 (ko) 2009-02-24
AU2002317482B2 (en) 2007-08-16
ES2319107T3 (es) 2009-05-04
CZ20033314A3 (cs) 2004-08-18
DK1404317T3 (da) 2009-02-23
HUP0400250A2 (hu) 2004-08-30
JP2011016835A (ja) 2011-01-27
CA2455296C (en) 2010-08-17
WO2003000252A1 (en) 2003-01-03
JP4683839B2 (ja) 2011-05-18
MXPA03011510A (es) 2004-03-18
HK1068792A1 (zh) 2005-05-06
JP2004534816A (ja) 2004-11-18
ITRM20010356A0 (it) 2001-06-21
SK382004A3 (en) 2004-05-04
CA2455296A1 (en) 2003-01-03
SK287828B6 (sk) 2011-11-04
PL367618A1 (en) 2005-03-07
US7098233B2 (en) 2006-08-29
EP1404317A1 (en) 2004-04-07
KR20040032113A (ko) 2004-04-14
US20040235899A1 (en) 2004-11-25
CN1535146A (zh) 2004-10-06
ATE416767T1 (de) 2008-12-15
EP1404317B1 (en) 2008-12-10
CN100482223C (zh) 2009-04-29
HUP0400250A3 (en) 2008-03-28

Similar Documents

Publication Publication Date Title
ATE416767T1 (de) 5-halo-tryptaminderivate als 5-ht6 und/oder 5-ht7 rezeptorliganden
BR0210929A (pt) Derivados de indol com afinidade para o receptor 5-ht6
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
EA200200360A1 (ru) Производные пурина
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
AR021055A1 (es) Derivados de pirazolopiridina
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
BRPI0209216B8 (pt) derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos
NO20015226L (no) Tri-aryl syrederivater som PPAR reseptor ligander, farmasoytisk sammensetning omfattende samme og anvendelse av samme for fremstilling av medikament.
EA200400432A1 (ru) Производные мочевины
DK1175398T3 (da) Indolinderivater som progesteronantagonister
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
ATE417838T1 (de) Arylsulfonyl-derivate mit 5-ht 6-rezeptor- affinität
EA200300619A1 (ru) Серотонинергические средства
TR200100698T2 (tr) 5-HT4 alıcı-Antagonistleri olarak Dihidrobenzodioksin Karboksamit ve Keton türevleri
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
DE69708968D1 (de) Arylacrylamidderivate als 5HT1 Agoniste oder Antagoniste
PT1204658E (pt) Agonistas benzofurilpiperazina de serotonina
DE69711868D1 (de) Adenosin-derivate
ATE274515T1 (de) Pyrazolopyridinderivate
DK0516350T3 (da) 2-hydroxy-2-phenylethylamin-derivater som beta-3-adrenoceptoragonister
DK0982305T3 (da) Indan-1-ol-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende derivaterne
ATE170851T1 (de) Guanidinothiazolederivate und ihre anwendung als h2-rezeptor-antagonisten
ATE285771T1 (de) Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung